
Sign up to save your podcasts
Or


Brought to US Healthcare professionals by Acorda Therapeutics
Dr. Jennifer Durphy, Movement Disorders Specialist and Associate Professor of Neurology at Albany Medical Center, discusses treatment for the return of symptoms in Parkinson’s disease.
Ahlskog JE et al. Mov Disord. 2001;16(3):448-458., Brown RG et al. J Psychosom Res. 2015;78(2):143-148., Chou KL et al. Parkinsonism Relat Disord. 2018;51:9-16., Hechtner MC et al. Parkinsonism Relat Disord. 2014;20(9):969-974. Stacy M et al. Mov Disord. 2005;20(6):726-733., Stocchi F. et al. Parkinsonism Relat Disord. 2014;20(2):204-211., Vijiaratnam N, Foltynie T. Drugs. 2020;80: 775-796
Brought to US Healthcare professionals by Acorda Therapeutics
Dr. Ray Dorsey, the David M. Levy Professor of Neurology and Director of the Center for Health + Technology at the University of Rochester Medical Center, discusses the use of telemedicine in managing Parkinson’s disease. Dr. Dorsey discusses his own approach to telemedicine, the advantages and disadvantages of telemedicine in a neurology clinic, and the utility of telemedicine post COVID-19.
REFERENCES:
Brought to US Healthcare professionals by Acorda Therapeutics
Dr. Rajeev Kumar, Medical Director of the Rocky Mountain Movement Disorders Center, discusses the efficacy, safety, and patient selection for an as-needed treatment option for the return of Parkinson’s disease symptoms.
Brought to US Healthcare professionals by Acorda Therapeutics
Dr. Ron Pfeiffer, Professor, Department of Neurology, Oregon Health & Science University, discusses gastrointestinal complications in patients with Parkinson’s disease.
Brudek T, et al. J Parkinsons Dis. 2019;9(s2):S331-S344., Camci G, et al. J clin neurol. 2016;12(2):147-150., Chaing HL, et al. J Mov Disord. 2019;12(2):67-83., Chandra R, et al. JCI Insight. 2017;2(12)., Chou KL, et al. Parkinsonism Relat Disord. 2018;51:9-16., Deleu D, et al. Clin Pharmacokinet.
Brought to US Healthcare professionals by Acorda Therapeutics
Dr. Salima Brillman, Director of the Parkinson’s Disease and Movement Disorders Center of Silicon Valley, discusses the under treatment of OFF episodes in patients with Parkinson’s disease.
Ahlskog JE, et al. Mov Disord. 2001;16(3):448-458., Armstrong MJ, et al. PLoS One.
From the publisher's feed